Description
Veracyte, Inc. is a diagnostics company focused on molecular cytology. The Company focuses on diseases that often require invasive procedures for an accurate diagnosis. The Company discovers, develops and commercializes molecular diagnostic solutions that enable physicians to make informed treatment decisions early, thus helping patients avoid unnecessary invasive procedures The Company’s first commercial solution is Afirma Thyroid FNA Analysis which include Gene Expression Classifier (GEC). The GEC employs a 142-gene signature to preoperatively determine whether thyroid nodules previously classified by cytopathology as indeterminate can be reclassified as benign. The Company operates in South San Francisco, California and Austin, Texas.
Address
Suite 250, 7000 Shoreline Court
SOUTH SAN FRANCISCO, CA 94080
United States
SOUTH SAN FRANCISCO, CA 94080
United States
Website
www.veracyte.comKey stats and ratios
| Q2 (Jun '13) | 2012 | |
| Net profit margin | -128.06% | -160.38% |
| Operating margin | -106.89% | -162.79% |
| EBITD margin | - | -156.72% |
| Return on average assets | -132.35% | -126.36% |
| Return on average equity | - | - |
| Employees | 107 |
No comments:
Post a Comment